Mechanisms Dashboard

Mechanisms Dashboard

Overview

The Mechanisms Dashboard provides a comprehensive overview of neurodegenerative disease in NeuroWiki. This page serves as a central navigation hub for finding mechanism information by pathway, disease relevance, and therapeutic targetability. The dashboard aggregates our growing knowledge base of molecular pathways, protein interactions, and cellular that drive neurodegeneration in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and related disorders.[@kegg]

Quick Stats

| Metric | Value | [@nature]
|--------|-------| [@cellular]
| Total Mechanism Pages | 871 |
| Alzheimer's Mechanisms | ~200 |
| Parkinson's Mechanisms | ~150 |
| ALS Mechanisms | ~120 |
| Pathway Pages | ~50 |
| Therapeutic Targets | ~300 |

Introduction to Neurodegenerative Mechanisms

Neurodegenerative share common mechanistic themes despite their distinct clinical presentations. Understanding these shared pathways is critical for developing disease-modifying therapies. The major include:

Protein Misfolding and Aggregation

Mechanisms Dashboard

Overview

The Mechanisms Dashboard provides a comprehensive overview of neurodegenerative disease in NeuroWiki. This page serves as a central navigation hub for finding mechanism information by pathway, disease relevance, and therapeutic targetability. The dashboard aggregates our growing knowledge base of molecular pathways, protein interactions, and cellular that drive neurodegeneration in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and related disorders.[@kegg]

Quick Stats

| Metric | Value | [@nature]
|--------|-------| [@cellular]
| Total Mechanism Pages | 871 |
| Alzheimer's Mechanisms | ~200 |
| Parkinson's Mechanisms | ~150 |
| ALS Mechanisms | ~120 |
| Pathway Pages | ~50 |
| Therapeutic Targets | ~300 |

Introduction to Neurodegenerative Mechanisms

Neurodegenerative share common mechanistic themes despite their distinct clinical presentations. Understanding these shared pathways is critical for developing disease-modifying therapies. The major include:

Protein Misfolding and Aggregation

The accumulation of misfolded is a hallmark of most neurodegenerative . In Alzheimer's Disease, amyloid-beta (Aβ) peptides form extracellular plaques while [tau protein](/entities/tau-protein) creates neurofibrillary tangles inside [neurons](/entities/neurons). In Parkinson's Disease, alpha-synuclein aggregates into Lewy bodies. ALS features TDP-43 and SOD1 protein aggregates. These misfolded propagate between cells in a prion-like manner, spreading pathology throughout the nervous system.[@prionlike2020]

Cellular Senescence and Aging

Cellular senescence contributes significantly to neurodegenerative processes. Microglial senescence leads to chronic neuroinflammation and impaired phagocytosis. Neuronal senescence prevents regeneration and maintenance of synaptic connections. The senescence-associated secretory phenotype (SASP) releases pro-inflammatory cytokines that accelerate disease progression.[@cellular2022]

Mitochondrial Dysfunction

Mitochondrial dysfunction is central to neurodegeneration. Impaired complex I activity in the substantia nigra is a hallmark of Parkinson's Disease. Reduced ATP production leads to energy failure, calcium dysregulation, and increased [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) production. Mitochondrial DNA mutations accumulate with age, and mitophagy defects prevent the removal of damaged mitochondria.[@mitochondrial2021]

Neuroinflammation

Chronic neuroinflammation drives disease progression across all neurodegenerative conditions. Microglial activation releases pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. The [NLRP3 inflammasome](/entities/nlrp3-inflammasome) plays a critical role in microglial activation. [Complement system](/entities/complement-system) activation promotes synaptic pruning and neuronal loss. Disease-associated [microglia](/cell-types/microglia-neuroinflammation) (DAM) represent a specific activation state linked to neurodegeneration.[@neuroinflammation2023]

Navigation

By Mechanism Category

• Mechanisms Overview — Comprehensive mechanism guide
• Mechanism Rankings — Ranked therapeutic targets
• Mechanism Categories & Pathways — Pathway organized
• Therapeutic Targetability — Drug development readiness

By Disease Mechanism

• Alzheimer's Disease: Amyloid Cascade, Tau Pathology, Neuroinflammation
• Parkinson's Disease: Alpha-Synuclein Aggregation, Mitochondrial Dysfunction, LRRK2 Pathway
• ALS: TDP-43 Pathology, SOD1 Aggregation, RNA Metabolism

By Pathway Type

• Protein Aggregation
• Cell Death Pathways
• Neuroinflammation
• Synaptic Dysfunction
• Metabolic Dysfunction

Key Mechanisms by Disease

Alzheimer's Disease Mechanisms

Alzheimer's Disease is characterized by two pathological hallmarks: amyloid plaques composed of amyloid-beta peptides and neurofibrillary tangles composed of hyperphosphorylated tau protein. Beyond these hallmark pathologies, numerous interconnected drive disease progression.

| Mechanism | Therapeutic Target | Evidence Level |
|-----------|-------------------|---------------|
| Amyloid-beta Aggregation | BACE, Amyloid antibodies | High |
| Tau Pathology | Tau kinases, antibodies | High |
| Neuroinflammation | TREM2, CD33 | Medium-High |
| Synaptic Loss | Synaptic plasticity modulators | Medium |
| Metabolic Dysfunction | Metabolic enhancers | Medium |

Core Disease Mechanisms

Amyloid Cascade Hypothesis: The amyloid cascade hypothesis posits that amyloid-beta accumulation initiates a cascade leading to tau pathology, synaptic loss, and cognitive decline. Amyloid-beta oligomers are considered the toxic species that impair synaptic function. BACE (beta-secretase) and [gamma-secretase](/entities/gamma-secretase) inhibitors have been developed to reduce amyloid-beta production, though clinical trials have пока failed to demonstrate clinical benefit.[@amyloidbeta2024]

Tau Pathology: Tau protein normally stabilizes microtubules in neurons. In AD, tau becomes hyperphosphorylated, leading to microtubule disassembly and aggregation into neurofibrillary tangles. Tau spreads through neural circuits in a predictable pattern correlated with clinical progression. Tau immunotherapy aims to remove pathological tau from the brain.[@tau2022]

Neuroinflammation: Microglial activation is a prominent feature of AD brains. The TREM2 gene variants significantly modify AD risk, highlighting the importance of microglial function. CD33 variants also influence microglial phagocytosis of amyloid-beta. Disease-associated microglia (DAM) represent an activated state that may be both protective and harmful.[@trem2023]

Synaptic Dysfunction: Synaptic loss correlates better with cognitive impairment than amyloid or tau burden. Amyloid-beta oligomers directly impair synaptic function. Microglial synaptic pruning becomes dysregulated in AD. The complement system (C1q, C3) tags synapses for elimination by microglia.[@synaptic2022]

Parkinson's Disease Mechanisms

Parkinson's Disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies composed of alpha-synuclein. Multiple contribute to neuronal death.

| Mechanism | Therapeutic Target | Evidence Level |
|-----------|-------------------|---------------|
| Alpha-Synuclein | Aggregation inhibitors | High |
| Mitochondrial Dysfunction | Complex I enhancers | Medium-High |
| LRRK2 | LRRK2 inhibitors | Medium-High |
| Neuroinflammation | Microglial modulators | Medium |
| Autophagy Defects | Autophagy enhancers | Medium |

Core Disease Mechanisms

Alpha-Synuclein Aggregation: Alpha-synuclein is a presynaptic protein that can misfold and aggregate into soluble oligomers and insoluble fibrils. Mutations in the SNCA gene (duplication, triplication, point mutations) cause familial PD. The prion-like propagation of alpha-synuclein explains the spreading pattern of pathology through the nervous system.[@alphasynuclein2021]

Mitochondrial Dysfunction: Complex I deficiency is a consistent finding in PD brains. Environmental toxins that inhibit complex I (MPTP, rotenone) can produce PD-like phenotypes. PINK1 and Parkin mutations cause familial PD through impaired mitophagy. The PINK1-Parkin pathway is critical for removing damaged mitochondria.[@pink2020]

LRRK2 Pathway: Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of familial PD. LRRK2 is involved in synaptic function, autophagy, and cytoskeletal dynamics. G2019S is the most common pathogenic variant. LRRK2 inhibitors are in clinical development.[@lrrk2023]

Neuroinflammation: Microglial activation in the substantia nigra contributes to dopaminergic neuron loss. The NLRP3 inflammasome is activated in PD. Pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α are elevated in PD brains and CSF.[@neuroinflammation2022]

ALS Mechanisms

Amyotrophic Lateral Sclerosis (ALS) is characterized by progressive loss of upper and lower motor neurons. Most cases are sporadic, but C9orf72, SOD1, FUS, and TARDBP mutations cause familial forms.

| Mechanism | Therapeutic Target | Evidence Level |
|-----------|-------------------|---------------|
| SOD1 Aggregation | ASO, antibodies | High |
| TDP-43 Pathology | Splicing modulators | Medium-High |
| RNA Metabolism | RNA-binding | Medium |
| Excitotoxicity | Glutamate modulators | Medium |
| Mitochondrial Dysfunction | Antioxidants | Medium |

Core Disease Mechanisms

SOD1 Aggregation: Mutations in SOD1 cause ~20% of familial ALS. Mutant SOD1 acquires toxic properties including aggregation. The exact mechanism of toxicity is unknown but may involve mitochondrial dysfunction, excitotoxicity, and impaired axonal transport. ASO therapy targeting SOD1 mRNA has been approved.[@sod2022]

TDP-43 Pathology: TDP-43 (encoded by TARDBP) is an RNA-binding protein that forms inclusions in >95% of ALS cases (including sporadic cases). TDP-43 is involved in RNA splicing, transport, and translation. Mutations cause familial ALS through gain-of-toxic-function .[@tdp2021]

C9orf72 Repeat Expansion: The most common genetic cause of ALS is a hexanucleotide repeat expansion in the C9orf72 gene. The expansion leads to toxic RNA foci and dipeptide repeat that interfere with multiple cellular processes including nucleocytoplasmic transport and autophagy.[@corf2022]

Excitotoxicity: Motor neurons are particularly vulnerable to glutamate-induced excitotoxicity. Reduced glutamate transporter (EAAT2) expression leads to increased extracellular glutamate. Riluzole, which reduces glutamate release, is the only disease-modifying drug approved for ALS.[@excitotoxicity2021]

Therapeutic Target Rankings

Highest Priority Targets

| Target | Disease | Modality | Development Stage |
|--------|---------|----------|-------------------|
| Amyloid-beta | AD | Antibody, Small molecule | Approved/Phase 3 |
| Tau | AD | Antibody, Kinase inhibitor | Phase 2/3 |
| Alpha-synuclein | PD | Antibody, Aggregation inhibitor | Phase 2 |
| LRRK2 | PD | Small molecule inhibitor | Phase 2 |
| TREM2 | AD | Antibody, Agonist | Phase 1/2 |
| SOD1 | ALS | ASO, Antibody | Approved/Phase 3 |

Emerging Targets

| Target | Mechanism | Promise |
|--------|-----------|---------|
| PIKfyve | Autophagy | High |
| USP30 | Mitophagy | Medium-High |
| c-Abl | Alpha-synuclein | Medium |
| [GBA](/entities/gba) | Alpha-synuclein | Medium-High |
| NLRP3 | Neuroinflammation | Medium |

Target Development by Disease

Alzheimer's Disease Pipeline

The AD therapeutic pipeline includes disease-modifying agents targeting amyloid-beta, tau, and neuroinflammation. [Lecanemab](/entities/lecanemab) and [donanemab](/entities/donanemab) have demonstrated slowing of cognitive decline in recent trials. Anti-tau antibodies are in late-stage development. TREM2 agonists represent a novel approach to enhance microglial function.[@alzheimers2024]

Parkinson's Disease Pipeline

PD therapeutic development focuses on disease modification rather than symptomatic treatment. Alpha-synuclein aggregation inhibitors, LRRK2 inhibitors, and GBA modulators are in clinical trials. Gene therapy approaches for GBA and other targets are advancing. Cell replacement therapy using dopaminergic precursors is under investigation.[@parkinsons2023]

ALS Pipeline

The ALS pipeline has expanded significantly. Tofersen (ASO for SOD1) has received approval. Gene therapies for C9orf72 and other targets are in development. Small molecules targeting excitotoxicity, mitochondrial dysfunction, and neuroinflammation continue to be evaluated. Biomarker development is critical for accelerating clinical trials.@als2024]

Pathway Maps

Key Pathways

• Amyloid Cascade Hypothesis
• Tau Propagation Pathway
• Alpha-Synuclein Spreading
• Mitochondrial Quality Control
• Neuroimmune Axis

Integrated Disease Models

The mechanistic understanding of neurodegeneration has evolved toward integrated models that explain how multiple pathways interact:

Protein Aggregation-Seeding Model: Misfolded act as seeds that template the conversion of normal into the aggregated form. This prion-like mechanism explains the spreading pattern of pathology through connected brain regions.

Inflammation-Cycling Model: Initial inflammation may be protective, but chronic inflammation becomes self-perpetuating. Microglial senescence contributes to the inflammatory burden. The cycle of neuroinflammation, protein aggregation, and neuronal dysfunction drives progressive disease.

Cellular Energy Failure Model: Mitochondrial dysfunction leads to reduced ATP, increased ROS, and calcium dysregulation. Energy failure impairs autophagy, leading to accumulation of damaged and organelles. This creates a vicious cycle accelerating neurodegeneration.

Cross-Links

Related Sections

• Treatments — Therapeutic interventions
• Biomarkers — Mechanism
• Genes — Disease genes
• Proteins — Target
• Cell Types — Cell vulnerability

External Resources

• Alzheimer's Drug Discovery Foundation
• Parkinson's Progression Markers Initiative
• ALS(//amyotrophic-lateral-sclerosis) Therapy Development Institute
• NIH Blueprint for Neuroscience

See Also

• Mechanisms Overview
• Mechanism Rankings
• Mechanism Categories & Pathways
• Therapeutic Targetability
• [Amyloid Cascade](/mechanisms/amyloid-cascade)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Alpha-Synuclein Aggregation](/proteins/alpha-synuclein)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [LRRK2 Pathway](/mechanisms/lrrk2-pathway)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](/pathways)

Detailed Mechanism Categories

Protein Homeostasis Mechanisms

Protein homeostasis (proteostasis) is essential for neuronal health. The proteostasis network includes molecular chaperones, the [ubiquitin-proteasome system](/entities/ubiquitin-proteasome-system) (UPS), and autophagy. Disruption of any component can lead to protein aggregation and neurodegeneration.

Molecular Chaperones

Molecular chaperones assist protein folding and prevent aggregation. Heat shock (HSPs) including HSP70, HSP90, and small HSPs are critical for proteostasis. In neurodegenerative , chaperone activity becomes overwhelmed or impaired. Hsp90 inhibitors have been explored as a therapeutic approach to activate chaperone-mediated clearance of mutant .[@hsp2021]

Ubiquitin-Proteasome System

The UPS degrades most intracellular . Ubiquitin chains mark for degradation by the 26S proteasome. Parkin is an E3 ubiquitin ligase that tags damaged mitochondria for removal. Mutations in Parkin and PINK1 cause familial PD. UPS impairment is observed in multiple neurodegenerative .[@parkin2020]

Autophagy-Lysosome Pathway

Autophagy degrades large protein aggregates and damaged organelles. Three main types exist: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). In macroautophagy, double-membraned autophagosomes fuse with lysosomes. CMA directly imports specific into lysosomes. LAMP-2A is the receptor for CMA. Defects in autophagy are common in neurodegeneration.[@autophagy2021]

Cellular Stress Responses

Oxidative Stress

Reactive oxygen species (ROS) are produced by mitochondria and various enzymes. Antioxidant systems including superoxide dismutase (SOD), catalase, and glutathione peroxidase normally neutralize ROS. In neurodegeneration, oxidative stress increases while antioxidant capacity decreases. Elevated oxidative damage to DNA, lipids, and is observed in AD, PD, and ALS.[@oxidative2021]

Endoplasmic Reticulum Stress

The endoplasmic reticulum (ER) is the site of protein folding. Various stresses can cause ER stress and trigger the [unfolded protein response](/entities/unfolded-protein-response) (UPR). Three ER stress sensors (PERK, IRE1, ATF6) coordinate the UPR. Chronic ER stress leads to apoptosis. ER stress is implicated in all major neurodegenerative .[@stress2022]

DNA Damage Response

Neurons are particularly vulnerable to DNA damage due to their non-dividing state. DNA damage accumulates with age. The DNA damage response (DDR) includes detection, signaling, and repair pathways. Defective DNA repair is observed in AD and PD. ATM, ATR, and p53 are key DDR . Chronic DDR activation leads to cellular senescence.[@dna2022]

Synaptic Mechanisms

Synaptic Vesicle Cycling

Synaptic vesicles undergo cycles of fusion, release, and recycling. Synuclein normally associates with synaptic vesicles and may regulate vesicle cycling. Disruption of vesicle cycling leads to impaired neurotransmitter release. Clathrin-mediated endocytosis is the primary vesicle recycling mechanism. Proteins involved in vesicle cycling are implicated in neurodegeneration.[@synaptic2022a]

Calcium Homeostasis

Calcium signaling is essential for synaptic transmission and neuronal survival. Calcium dysregulation leads to excitotoxicity. Store-operated calcium entry (SOCE) is impaired in AD. Ryanodine receptors and IP3 receptors mediate calcium release from internal stores. Calcium buffer including calbindin provide neuroprotection.[@calcium2021]

Axonal Transport

Neurons rely on axonal transport for protein and organelle movement between cell body and synapse. Microtubules serve as tracks for motor (kinesins, dyneins). Axonal transport defects are early events in neurodegeneration. Tau hyperphosphorylation disrupts microtubule function. Mutations in transport cause familial ALS.[@axonal2021]

Glial Mechanisms

Microglia

Microglia are the brain's immune cells. They survey the environment and respond to injury or infection. In neurodegeneration, microglia become chronically activated. TREM2 is a critical microglial receptor that recognizes amyloid and other pathological substrates. Disease-associated microglia (DAM) are a specific activation state found in AD and other conditions.[@axonal2021]

Astrocytes

[Astrocytes](/entities/astrocytes) support neuronal metabolism and function. They take up glutamate, provide metabolic support, and maintain the [blood-brain barrier](/entities/blood-brain-barrier). Astrocyte dysfunction contributes to neurodegeneration. In ALS, astrocytes become toxic to motor neurons. Reactive astrocytes are observed in AD and PD.[@astrocyte2022]

Oligodendrocytes

Oligodendrocytes produce myelin sheaths around axons. Oligodendrocyte loss is a feature of multiple sclerosis but also occurs in AD and PD. Myelin breakdown leads to conduction deficits and axonal degeneration. Iron accumulation in oligodendrocytes is observed in PD.[@oligodendrocyte2022]

Metabolic Mechanisms

Glucose Metabolism

Neurons require constant glucose supply for energy. Brain glucose metabolism declines with age and even more dramatically in AD. FDG-PET measures cerebral glucose metabolism as a biomarker. Insulin signaling impairment (type 2 diabetes) increases AD risk. Astrocyte-neuron lactate transport supports metabolic coupling.[@brain2021]

Lipid Metabolism

Lipids are essential for neuronal membrane composition and synaptic function. Cholesterol metabolism is altered in AD. The APOE gene (APOE4 allele increases AD risk) is involved in lipid transport. Lipid droplets accumulate in neurons and glia with aging and neurodegeneration. Fatty acid oxidation generates ROS.[@lipid2022]

Iron Metabolism

Iron accumulation is observed in multiple neurodegenerative . In PD, neuromelanin-bound iron is released from dying neurons, creating a toxic cycle. Iron chelation therapy has been explored in AD and PD. Ferritin stores iron safely. DMT1 and ferroportin regulate iron import and export.[@iron2022]

Cell Death Mechanisms

Apoptosis

Apoptosis is a programmed cell death pathway. The intrinsic pathway involves mitochondria and caspase-9. The extrinsic pathway involves death receptors and caspase-8. Both pathways converge on caspase-3 executioner caspases. Anti-apoptotic including Bcl-2 are neuroprotective. Pro-apoptotic including Bax promote cell death.[@apoptosis2021]

Necroptosis

Necroptosis is a form of regulated necrosis. RIPK1, RIPK3, and MLKL are key mediators. Necroptosis is implicated in AD, PD, and ALS. Inhibition of necroptosis may provide neuroprotection. It can be triggered by TNF-α and other signals.[@necroptosis2022]

Ferroptosis

Ferroptosis is an iron-dependent form of cell death characterized by lipid peroxidation. GPX4 is the key antioxidant enzyme. Ferroptosis is implicated in PD and ALS. Ferroptosis inhibitors are neuroprotective in animal models. System Xc- imports cystine for glutathione synthesis.[@ferroptosis2022]

Genetic Risk Factors

Apolipoprotein E (APOE)

APOE4 is the strongest genetic risk factor for sporadic AD. APOE is produced by astrocytes and microglia. APOE4 has reduced lipid transport function compared to APOE3. APOE4 carriers have increased amyloid deposition. APOE-targeted therapies are in development.[@apoe2023]

TREM2

TREM2 variants (including R47H) significantly increase AD risk. TREM2 is expressed in microglia. It recognizes amyloid, lipids, and other ligands. TREM2 signaling activates microglial phagocytosis. Loss-of-function variants impair microglial function. TREM2 agonists are in clinical development.[@trem2023a]

CD33

CD33 is a sialic acid-binding lectin that regulates microglial phagocytosis. The CD33 protective allele reduces expression. Increased CD33 expression impairs Aβ clearance. CD33 is a therapeutic target. Anti-CD33 antibodies are being developed.[@neuron2019]
[@hsp2021]: Hsp90 and neurodegeneration (Nature Reviews Drug Discovery, 2021)
[@parkin2020]: Parkin and PINK1 in Parkinson's disease (Nature Reviews Neurology, 2020)
[@autophagy2021]: Autophagy in neurodegenerative (Nature Reviews Neurology, 2021)
[@oxidative2021]: Oxidative stress in neurodegeneration (Free Radical Biology & Medicine, 2021)
@stress2022]: ER stress(//endoplasmic-reticulum-stress) in neurodegeneration (Cell Death & Disease, 2022)
@dna2022]: DNA damage(//dna-damage-repair) in aging and neurodegeneration (Nature Reviews Neuroscience, 2022)
[@synaptic2022a]: Synaptic vesicle cycling in neurodegeneration (Synapse, 2022)
[@calcium2021]: Calcium dysregulation in AD (Cell Calcium, 2021)
[@axonal2021]: Axonal transport defects in neurodegeneration (Journal of Neuroscience, 2021)
[@astrocyte2022]: Astrocyte dysfunction in ALS (Nature Reviews Neurology, 2022)
[@oligodendrocyte2022]: Oligodendrocyte dysfunction in neurodegeneration (Glia, 2022)
[@brain2021]: Brain glucose metabolism in AD (Nature Reviews Neurology, 2021)
[@lipid2022]: Lipid metabolism in neurodegeneration (Nature Reviews Neurology, 2022)
[@iron2022]: Iron metabolism in PD (Movement Disorders, 2022)
[@apoptosis2021]: Apoptosis in neurodegeneration (Cell Death & Disease, 2021)
[@necroptosis2022]: Necroptosis in neurodegeneration (Cell Reports, 2022)
[@ferroptosis2022]: Ferroptosis in PD (Journal of Neural Transmission, 2022)
[@apoe2023]: APOE and Alzheimer's disease (Nature Reviews Neurology, 2023)
@trem2023a]: TREM2(//trem2) in AD (Molecular Psychiatry, 2023)
[@neuron2019]: CD33 in AD (Neuron, 2019)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Mechanisms Dashboard discovered through SciDEX knowledge graph analysis: